Fluidigm Q1 Revenues Grow 4 Percent, Miss Wall Street Estimate | GenomeWeb

NEW YORK (GenomeWeb) – Fluidigm said after the close of the market on Thursday that its first quarter revenues grew 4 percent year over year.

For the three months ended March 31, the South San Francisco, California-based life science research tools firm reported revenues of $26.7 million, up from $25.7 million in the year-ago period, but short of the Wall Street estimate of $30.7 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.